

Verification-Based Approaches to Bone-Conduction Amplification: Using Objective Measurements to Shape Clinical Practices

October 7, 2024 25th Canadian Academy of Audiology Conference, Delta Grand Okanagan Resort, Kelowna, BC

> Alex Gascon, B.Sc., MPA., R.Aud, PhD Candidate PhD Supervisor: Dr. Bill Hodgetts, R.Aud, PhD

Institute for Reconstructive Sciences in Medicine - Misericordia Community Hospital, Edmonton, AB Department of Communication Sciences and Disorders - Faculty of Rehabilitation Medicine, University of Alberta





No conflict of interest to declare

Learning objectives

- Review bone-conduction hearing implant candidacy considerations for various types of hearing losses
- Review current and upcoming verification tools in bone-conduction amplification
- Explore how verification tools can support clinical practices in boneconduction amplification
- Understand the differences between bone-conduction hearing thresholds in diagnostic assessments and for device fitting purposes











Shaping Practice with BCD Verification

Audiometric vs. In-Situ Bone-Conduction Hearing thresholds

- Assessing typical fitting characteristics of percutaneous BCD in conductive and mixed hearing losses
- Predicting BCD aided-audibility to help with implant candidacy and device decision

DSL BCD fitting and verification procedure
RETFL: Calibration of audiometric BC transducer vs. BCD *In-situ* BC testing

BC: A Different Path to the Cochlea

- Historical considerations
- Osseointegration and percutaneous BCD



Bone-Conduction : An Alternative Path for Sounds to Reach the Inner Ear

Images retrieved from Drake, R. L. (2015)

- Bone-conduction hearing in human has been a known phenomenon since at least Antiquity
- Using bone-conduction hearing devices (BCD) for rehabilitation in individuals with hearing loss have been documented as early as the 1800s
- The physiological mechanisms of bone-conduction hearing were described by Georg Von Békésy in the early 1930s



Fig. 2. Fonifero, 1876.

Mudry and Tjellström, 2011



Bone tissue growing onto a titanium screw. Microscopy. Photo supplied by P.-I. Brånemark.



Professor Brånemark and his first patient, Gösta Larsson, photographed in 1990. Gösta Larsson had just undergone surgery for a bone-anchored hearing aid. Photo supplied by Nobelpharma.

Pictures retrieved from A Matter of Balance, 1992, Elaine Williams





Skull-simulator measurement and Force-level-o-gram



dB FL on skull simulator + microphone location effects + RHCD = dB FL on abutment

DSL-BCD v1.1 Targets

- In-situ thresholds (RETFLdbc)
- Device characteristics:
 - MFO
 - RHCD
- Pediatric DSL BCD targets
- Monaural/Binaural fitting



Frequency (Hz)



Dotted line = 0 dB DL from 250 to 8000 Hz

<u>Input</u>

ex. International Speech Test Signal

- levels: 55, 65 and 75 dB
- MFO (90 dB Tone Sweep)
- Etc.

DSL BCD fitting procedure













Reference Equivalent Threshold Force Level dbc

Frequency (Hz)	250	500	750	1000	1500	2000	3000	4000	6000	8000
RETFLdbc (dB FL)	59.5	48.0		45.5	34.5	26.0	28.0	27.5	27.5*	27.5*
RETFL ANSI S3.6 2010 (dB FL)	67.0	58.0	48.5	42.5	36.5	31.0	30.0	35.5	40.0	40.0

Real-Head to Coupler Difference

(Frequency and device specific, ~ less than 3 dB)

In-situ BC threshold in dB Force Level = $RETFL_{dbc}$ + In-situ thresholds + RHCD

Ex. At 2 kHz, for an in-situ threshold of 30 dB DL, for this BCD model, the dB FL on abutment is 56 dB FL

Normal sloping moderate mixed : *in-situ* dB DL to dB FL







In-situ BC Thresholds vs. Audiometric BC Thresholds

RETFL_{dbc} (percutaneous, direct drive)

dB Dial Level (dB DL)

<u>A mixture of ipsi-lateral and contro-lateral</u> <u>responses from one, or both cochlea</u>

Purpose: BCD verification and fitting



RETFL ANSI S3.6 (transcutaneous, transducer on steelband)

dB Hearing Level (dB HL)

<u>Response from one cochlea (ANSI norm obtained with controlateral masking)</u>

Purpose: diagnostic, assess for conductive/mixed/sensorineural







A. Gascon, A.V. Ostevik, T. Huynh et al.

20

30

40 dB HL

50

60

70

80

90

100

Hearing Research 421 (2022) 108491



Fig. 3. On each figure, the blue line represents the average B71 bone conduction hearing thresholds in dB HL for the BCD user participants. Whiskers indicate +/- 1 standard deviation. In a) and b), squares represent the average bone-conduction hearing thresholds in dB "HL" obtained in-situ percutaneously. Average in-situ percutaneous boneconduction hearing thresholds for the Ponto 3 SP are shown in a), and for the BAHA 5 P in b).

Frequency (Hz)	250	500	750	1000	1500	2000	3000	4000	6000	8000
RETFLdbc (dB FL)	59.5	48.0		45.5	34.5	26.0	28.0	27.5	27.5*	27.5*
RETFL ANSI S3.6 2010 (dB FL)	67.0	58.0	48.5	42.5	36.5	31.0	30.0	35.5	40.0	40.0







Fig. 4. On each figure, the blue line represents the average B71 bone conduction hearing thresholds in dB HL for the BCD user participants. Whiskers indicate +/- 1 standard deviation. In a) and b), triangles represent the average bone-conduction hearing thresholds in dB "HL" obtained in-situ transcutaneously on the softband. Average in-situ transcutaneous bone-conduction hearing thresholds for the Ponto Super Power are shown in a), and for the BAHA 5 P in b).

BCD with non-surgical attachment





Speechmap/DSL-BCD adult



In this example, 20 dB DL with the device on the elastic head band was required to generate a response (i.e., hearing threshold).

This level was sufficient to overcome:

- Cochlear loss (if any)
- Skin attenuation loss
- Other loss of signal (ex. headband coupling mechanism, hair)

2023 Version 2023.01 Protocol for the Provision of Amplification



Key points – BC thresholds

- In-situ BC fitting thresholds are unmasked bone-conduction hearing thresholds obtained with the patient's personal BCD connected to their head
 - Used for BCD fitting and verification purposes (see DSL-BCD fitting procedure and UWO PedAmp 2023→ Hodgetts and Scollie, 2017, Bagatto et al., 2023)
 - Expected to be different than audiometric BC thresholds due to skin attenuation, calibration, contact force and contact size differences between the transducers/coupling methods
 - *In-situ* BC thresholds should be measured with all types of BCD coupling (i.e., soft elastic headband, abutment, etc.) whenever possible, although some BCD do not have *in-situ* testing capabilities



DSL-BCD v1.1 (Hodgetts and Scollie, 2017)

- Adapted from DSL v5.0 prescriptive algorithm (air-conduction hearing aids)
- Developed with a sample of adult BCD users (skin-penetrating abutment), monaurally aided (N=39)



Image retrieved from https://www.audioscan.com/en/verifit2/

Research Questions

What does typical percutaneous skull-simulator measurements look like for percutaneous BCDs?

• Investigate a wide range of hearing loss

What are typical output-to-target deviations and aided SII for adult percutaneous BCD wearers?

<u>Goal</u>

 Provide a better understanding of typical BCD fitting characteristics for various types of hearing losses

Unpublished data, data analysis ongoing Alex Gascon, Marlene Bagatto, Susan D. Scollie, Cassandra Cowan and William E. Hodgetts

Methodology

- Health Research Ethics Board #Pro00125725 (University of Alberta)
- Retrospective chart review
 - 100 percutaneous BCD users (e.g., skin-penetrating abutment)
 → Cochlear BAHA, Oticon Medical Ponto
 - Demographic information
 - BCD model
 - Fitting characteristics, output in dB FL of the device set at daily use setting
 - Aided Speech Intelligibility Index (SII, calculated by the Verifit 2)
 - In-situ BC thresholds
- Descriptive statistics, regression analysis
 - SPSS 28, IBM
 - GraphPad Prism 10.0.02 (171) for macOS

R	250	500	750	1k	1k5	2k	3k	4k	6k	8k	10k	12k5
FL UCL	98	114	122	129	120	115	112	108	105	105		1
DL UCL												-
Target1	43	76	97	97	91	87	90	90	90	90		-
Test 1	44	72	81	93	91	91	84	82	76	70	53	36
Comparison 1												
Target2	98	109	117	124	116	109	108	105	104	104		
Test 2	73	100	113	124	118	114	109	106	107	91	78	75
Comparison 2				-								_
Target3	43	79	103	106	101	95	95	94	92	91		1
Test 3	48	76	90	104	101	99	93	91	81	75	62	40
Comparison 3			[-					-
Target4	41	72	92	91	86	81	86	87	88	88		-
Test 4	38	63	72	83	79	79	73	70	64	60	48	35
Comparison 4				-				ļ				1
FL Threshold	90	89	84	80	84	80	83	92	97	106		-
DL Threshold RHDD	30	40	35	40	50	55	55	65	70	80		
RETFL	60	50	50	40	33	25	28	28	28	27		



Target-to-output difference

BCD Output (dB FL) – DSL-BCD target (dB FL)



Results









Output-to-target deviations for the 65 dB SPL Speech Std. signal

Unpublished data, preliminary results, data analysis ongoing





Output-to-target deviations for the 65 dB SPL Speech Std. signal

In-situ 4PTA = 36 dB

Unpublished data, preliminary results, data analysis ongoing



Verifit 2 Speechmap/DSL-BCD adul BCD Test box 140 Right 40 130 dB FL Scale Audiometry 120 UCL Average 110 20-No 100 None re: Skull-Simulator 🕘 🗸 🖂 🖓 SII 🛛 🖓 💏 8800 9660 9660 0odc 00000 000000 В 00000 0 60 0 00 50 -20-N/A > Sp 40 2 30 ► Sp N/A -40-20 3 10 N/A 4 N/A --60-250 4000 1600 .25 .5 6 8 2 1 4 6 In-situ 4PTA = 46 dB Frequency (kHz)

Output-to-target deviations for the 65 dB SPL Speech Std. signal

In-situ BC PTA Moderate (N = 20)

Unpublished data, preliminary results, data analysis ongoing



Aided Speech Intelligibility Index (SII) with Percutaneous BCD



Key points – typical fitting characteristics of percutaneous BCD fittings in adults

- DSL BCD targets are typically met with in-situ 4PTA better than ~40 dB
- As cochlear loss worsens, deviation to targets increases (output under targets), which is particularly noticeable at 4 kHz and above
 - Likely due to unstable gain and BCD Maximum Force Output limitations
- Data analysis ongoing

Limitations

- Retrospective chart review, BCD set at daily setting
- Whether fine tuning could have improved match to targets is not addressed by this study
- Aided SII → not a BC hearing measure, it was developed for air-conduction hearing

Potential BCA Candidate Inbox ×

Carmen Sandiego

Α

to me ╺

3:30 PM (2 minutes ago) 🙀 🕤 🚦

8 C

Could you look at the audiogram attached? I am wondering if I should refer for a bone-conduction implant candidacy assessment. The bone line is not great, but the patient is not doing well with their hearing aids. See audio attached.

Let me know what you think, merci





Introducing the Baha® 6 Max Sound Processor: Small never sounded this powerful

• Premium-power sound processor in a small size with a 55dB SNHL fitting range¹



Fitting range 55 dB

55 dB Fitting range

The Osia 2 System is indicated for individuals with bone conduction thresholds within the yellow area indicated in the fitting range. For further details, see the candidate selection guide.¹



Pier Conduction Threshold Diagonal Conduction Threshold Diagonal Conduction Threshold Diagonal Conduction Threshold Diagonal Conduction Frequency (Hz) Bone-conduction thresholds = 55 dB HL averaged across 500, 1000, 2000, and 4000 Hz Air-conduction thresholds may extend into this area

Images retrieved from:

Cochlear.com

https://www.audiologyonline.com/interviews/med-el-celebrating-10-years-bonebridge-27886Oticonmedical Oticonmedical.com



?





Objective

A better understanding of the relationship between pre-surgical hearing thresholds (diagnostic BC thresholds) and percutaneous BCD verification characteristics (aided audibility measured with skull-simulator)

Research Questions

- 1. Can <u>audiometric bone-conduction hearing thresholds</u> predict in-situ bone-conduction <u>hearing thresholds</u> obtained on a skin-penetrating bone-conduction hearing implant?
- 2. Can audiometric bone-conduction hearing thresholds predict the <u>output</u> of the BCD once connected to a bone-conduction hearing implant?



CAA Clinical Research Grant 2023

Methodology and Proposed Analysis

Design: quasi-experimental prospective study, repeated measure *Sample size: 100* (currently at 86 participants)

Inclusion criteria:

- Adults (≥ 18 years old)
- · Using a BCD connected to an osseointegrated implant with skin-penetrating abutment

Procedure

- Measure In-situ BC thresholds
- Measure audiometric BC threshold
- Store skull-simulator measurement with device set at "daily use", reflecting how the device is used in day-to-day situations (feedback management activated, accounts for device limitations related to MFO and unstable gain)

Proposed analysis:

• Regression analysis



- *In-Situ* pure-tone audiometry. *B*one-conduction hearing thresholds measured using the BCD as the transducer. Hearing thresholds are measured with the device connected to the abutment. Tones are presented with the hearing device software

Outcome Variable: InSituBC

Predictor: BCthresholds



p < 0.001 and large effect size for each model

Unpublished data, preliminary results, data analysis ongoing

Predicting output of the BCD

• Predictor: Diagnostic BC thresholds







Outcome variable:

- Predicted Output in dB FL, for a 65 dB speech signal, at 500, 1000, 2000 and 4000 Hz
- Device set a patient at patient daily use settings





Unpublished data, preliminary results, data analysis ongoing





Frequency (Hz)	500	1000	2000	4000
Unmasked Audiometric BC thresholds (dB HL)	30	45	55	65
Predicted in-situ BC thresholds (dB DL)	25	45	50	60





Predicted Speech Map for Percutaneous BCD on Abutment based on Audiometric BC Thresholds for the 65 dB ISTS Speech Signal





Frequency (HZ)	500	1000	2000	4000
Unmasked Audiometric BC thresholds (dB HL)	10	15	20	25
Predicted in-situ BC thresholds (dB DL)	10	15	15	30

Mixed Hearing Loss - Clinical case 1





• Word Recognition Score (NU6) on right: 100% at 100 dB HL

At 60 dB SPL aided with BICROS system

- CNC word : 62%
- CNC phoneme: 83%
- AZ Bio: 97%



Skull-simulator measurement at patient

Frequency (Hz)	500	1000	2000	4000
Unmasked Audiometric BC thresholds (dB HL)	50	60	40	25
Predicted in-situ BC thresholds (dB DL)	45	55	35	30

Prescription in software: DSL BCD Pediatric



- Provide another tool to support clinicians in their decision about:
 - Bone-conduction hearing implant candidacy
 - Device type (ex. regular vs. power device)
 - Bone-conduction implant type (current study is percutaneous with skinpenetrating abutment only)
- Current work:
 - Data collection ongoing
 - Eventually, develop a web-based tool to be used by clinicians (i.e., clinician enter unmasked audiometric threshold to generate a predicted Speech Map post-implant)
 - Extend data collection to active transcutaneous BCD measured using objective verification tool (Surface/skin microphone currently in prototype stage, under development)





Key points - Predicting BCD aided-audibility to help with implant candidacy and device decision

- The unmasked audiometric BC threshold at .5, 1, 2 and 4 kHz can predict the *in-situ* BC thresholds, BCD output and the aided SII in percutaneous fittings
 - *In-situ* BC threshold are more precisely predicted than the aided audibility (likely due to variability in user preferred settings)
 - This prediction can be used to generate an estimated predicted SpeechMap of the aided audibility fitting post-surgery
 - Further analysis needed to understand the size of the error of the predictions, and how to use this prediction as a clinical tool to help guide decisions surrounding the BCD

Final thoughts

- Audiologists have the training and knowledge to be an integral part of the decisions surrounding bone-conduction implant candidacy and device decisions
 - Aided audibility with the BCD should be a key factor in these decisions
- The bone-conduction amplification framework and verification tools are analogous to air-conduction amplification
 - Objective verification tools can be used to optimize fitting individually, and larger data set of BCD objective measurements in clinic are being gathered to help inform practice

Merci!

PhD Committee: Dr. Bill Hodgetts, Dr. Jacqueline Cummine, Dr. Marlene Bagatto, Dr. Daniel Aalto

iRSM team, iRSM BCD users, Rhys Kooistra, Dr. Marshall Chasin, Dr. Kathleen Jones, Dr. Susan Scollie, Cassandra Cowan, Hope Valeriote, Canadian Academy of Audiology, Mitchell Holmes, all the Albertan audiologists for their questions and collaboration Alex Gascon, R.Aud
Registered Audiologist, PhD Candidate
Bone-Conduction Amplification Laboratory – iRSM
Department of Communication Sciences and Disorders - Faculty of Rehabilitation Medicine, University of Alberta

agascon@ualberta.ca





